This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2009 Apr 11;373(9671):1225-6.

doi: 10.1016/S0140-6736(09)60704-2.

Glucocorticoid-induced osteoporosis: hope on the HORIZON

Luigi Gennari¹, John P Bilezikian

Affiliations

PMID: 19362657
DOI: 10.1016/S0140-6736(09)60704-2

Comment

Glucocorticoid-induced osteoporosis: hope on the HORIZON

Luigi Gennari et al. Lancet. 2009.

. 2009 Apr 11;373(9671):1225-6.

doi: 10.1016/S0140-6736(09)60704-2.

Authors

Luigi Gennari¹, John P Bilezikian

Affiliation

¹ Department of Internal Medicine, Endocrine Metabolic Sciences and Biochemistry, University of Siena, Siena 53100, Italy. gennari@unisi.it

PMID: 19362657
DOI: 10.1016/S0140-6736(09)60704-2

No abstract available

PubMed Disclaimer

Comment on

Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial.
Reid DM, Devogelaer JP, Saag K, Roux C, Lau CS, Reginster JY, Papanastasiou P, Ferreira A, Hartl F, Fashola T, Mesenbrink P, Sambrook PN; HORIZON investigators. Reid DM, et al. Lancet. 2009 Apr 11;373(9671):1253-63. doi: 10.1016/S0140-6736(09)60250-6. Lancet. 2009. PMID: 19362675 Clinical Trial.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information